Navigation Links
Cargill Receives Official Notification From FDA Supporting the Safety of Truvia(TM) Rebiana

New Natural Sweetener - Truvia(TM) Rebiana - Market Leader in New Sweetness Category

WAYZATA, Minn., Dec. 17 /PRNewswire/ -- Today, Cargill received official notification from the U.S. Food and Drug Administration (FDA) stating that the agency has no objection to the conclusion of an independent expert panel which reviewed research that rebaudioside A (rebiana), the identity in Truvia(TM) rebiana, is generally recognized as safe (GRAS) for use as a general purpose sweetener. The FDA letter affirms and supports rebiana's safety and the data used to make that determination.

"Given the extensive research conducted to assure the safety of Truvia(TM) rebiana, Cargill has tremendous confidence in the product. The FDA letter further validates what the science has concluded - that Truvia(TM) rebiana is safe for use for all consumers," said Marcelo Montero, president, Cargill Health & Nutrition. "The FDA brought the appropriate rigor to the process and we are extremely pleased with the news."

Truvia(TM) rebiana is a well-characterized, high-purity ingredient derived from the best tasting part of the stevia leaf. Cargill has spent the past five years developing the product to its specifications and working to produce the ingredient on a commercial scale. The high-purity ingredient - Truvia(TM) rebiana - is consistent in quality and composition. The FDA letter and the safety studies for Truvia(TM) rebiana pertain to only the high-purity products that meet the established criteria and not to all stevia.

In June 2008, the Joint FAO/WHO Expert Committee on Food Additives (JECFA) conducted a multi-year review of all the available scientific and clinical data on high purity steviol glycosides, including rebiana. In July 2008, the Committee determined that high purity, food-grade rebiana is safe for its intended use as a general-purpose sweetener, and established a permanent Acceptable Daily Intake (ADI). (

Cargill submitted a GRAS notification to the FDA on May 15, 2008.Prior to this, an independent expert panel convened in March 2008 to review the comprehensive safety dossier for rebiana that also included safety assurance of composition and quality of rebiana. The panel unanimously affirmed that rebiana is safe for its intended use as a general-purpose sweetener. Cargill published all the safety studies for scientific and public comment.

Cargill enlisted leading scientists to design and conduct a rigorous safety evaluation program for Truvia(TM) rebiana - the first such program to test a well-characterized, high-purity form of rebaudioside A. The comprehensive design of the studies and the peer-review process were the foundation of the research program for rebiana. These peer-reviewed, scientific studies, published in the scientific journal Food and Chemical Toxicology establish the safety of Truvia(TM) rebiana. ( Cargill is the only petitioner to the FDA that has made the safety dossier for rebiana publicly available as part of its GRAS notification.

Stevia is a shrub in the chrysanthemum family that is native to northeastern Paraguay. First discovered by natives of Paraguay, the plant has been grown, harvested and used in South America to sweeten foods and beverages for more than 200 years. The stevia leaf is a good source of natural, zero-calorie sweetness. Due to the fact that there are more than 200 varieties of the stevia plant, all stevia is not the same and stevia products currently on the market vary in their production, composition, purity level and sensory or taste characteristics. Cargill has applied its global expertise and knowledge in agriculture and agronomy to identify the varieties of stevia that will produce the best plants for each geography. Truvia(TM) rebiana comes from only from the best-tasting components of the stevia leaf and is a high-purity sweetener that is consistent in quality and taste.

"The search for a great tasting natural, zero calorie sweetener has been underway for more than three decades," added Zanna McFerson, business director for Cargill Health and Nutrition. "Consumer demand for non-caloric, natural sweeteners has increased over the years. Truvia(TM) natural sweetener is the first great tasting natural zero calorie sweetener available in the U.S. to meet that growing consumer demand."

About Truvia(TM)natural sweetener and ingredient

Truvia(TM) natural sweetener is a great tasting, natural, zero calorie tabletop sweetener, made with rebiana, derived from the best tasting part of the stevia leaf. Truvia(TM) natural sweetener is also an ingredient used to sweeten foods and beverages.For more information, visit

About Cargill

Headquartered in Minneapolis, Minn., Cargill is an international provider of food, agricultural and risk management products and services. With 160,000 employees in 67 countries, the company is committed to using its knowledge and experience to collaborate with customers to help them succeed. For more information, visit

      Media Contacts:
      Ann Clark Tucker                Atalanta Rafferty
      Phone: 952-742-4057             Phone: 212-994-7511
      Email:   Email:

SOURCE Cargill
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. E. Coli Registry Expanded for Victims of E. Coli Poisoning from Cargill Ground Beef
2. Volunteer for National Suicide Prevention Agency Earns Cargill Award
3. Cargill Executive Joins Blue Cross Board of Trustees
4. ChromaDex Partners With Cargill to Provide Global Quality Control Methods and Standards for Sweet Components of Stevia
5. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
6. DaVita Receives Civil Complaint
7. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
8. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
9. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
10. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
11. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
Post Your Comments:
(Date:12/1/2015)... CHICAGO (PRWEB) , ... December 01, 2015 , ... ... risk quantification and optimization of adjunctive imaging is the focus of numerous abstracts ... (RSNA) meeting, November 29-December 4, 2015. Nine abstracts highlight the use of ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... everything. That is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch ... product in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. (December ... the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis ... celebrates exceptional special needs providers that excel in synthesizing the areas of clinical ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... it has been awarded a fixed price per sprint agile development contract to ... at $34 million over five years, provides software engineering, infrastructure, as well as ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... clinical solutions for the care management and population health arenas, is pleased to ... clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ Management ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... VIEJO, Calif. , Dec. 1, 2015 /PRNewswire/ ... the prevalence of symptoms for pseudobulbar affect (PBA), ... outbursts of laughing and/or crying resulting from certain ... use of antipsychotic medications in nursing home residents, ... Geriatric Psychiatry. The study showed that almost one ...
(Date:12/1/2015)... , Dec. 1, 2015 Research and ... of the "2016 Global Enteric Disease Testing ... Salmonella, Shigella, Vibrio, Yersinia--France, Germany, Italy, Japan, Spain, ... Japan . --> ... The report is based on a combination ...
(Date:12/1/2015)... UPPSALA, Sverige, December 1, 2015 ... Breast Cancer Study Group (IBCSG, Bern ... att ingå i en klinisk studie av palbociclib, ... --> Studien, med namn PYTHIA, ... med anti-hormonella läkemedel i kombination med palbociclib, som ...
Breaking Medicine Technology: